PMS2

Across TCGA pan-cancer cohorts, PMS2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PMS2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PMS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PMS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where PMS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	18	view →
HNSC	DFS	Median	II,III,IV	0.196	0.697	.002	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.025	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	All	1.000	0.647	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PMS2–LUAD (OS)

Open the LUAD breakdown →